| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
Endogenous metabolite; cation-permeable ligand-gated ion channel (P2X purinergic receptor) agonist. CTP serves as a coenzyme in glycerophospholipid biosynthesis and protein glycosylation, and as a phosphate source for synthesis of amorphous calcium phosphate (ACP) nanoparticles and hydroxyapatite (HAP) microspheres. |
|---|---|
| ln Vitro |
As an endogenous metabolite, CTP is a substrate for RNA polymerases during transcription, and is converted to CDP-choline and CDP-ethanolamine for phospholipid synthesis. Substrate for CTP synthase (converts UTP to CTP). Participates in phospholipid synthesis and metabolism, passes through blood-CSF barrier. Has physiological role in coronary artery disease, lipid metabolism, and farnesol-induced apoptosis.
|
| ln Vivo |
CTP plays a physiological role in coronary artery disease, lipid metabolism, and farnesol-induced apoptosis. Involved in nucleotide and nucleic acid biosynthesis. Investigated for therapeutic effects in cerebral ischemia, traumatic brain injury, and neurodegenerative disorders due to its role in membrane phospholipid synthesis. Levels tightly regulated by de novo and salvage pathways.
|
| Enzyme Assay |
(1) P2X receptor binding: express human P2X receptors in HEK293 cells, treat with CTP (0.1-1000 uM), measure calcium influx (Fluo-4 AM) or patch-clamp to determine EC50. (2) CTP synthase assay: incubate CTP synthase (1-10 U) with UTP (1 mM), ATP (5 mM), glutamine (5 mM), Mg2+ buffer, measure CTP formation by HPLC at 280 nm.
|
| Cell Assay |
(1) Seed neuronal cells or hepatocytes in 6-well plates (1×10⁶ cells/well). (2) Treat with CTP disodium (0.1-10 mM) for 0-24 h. (3) For uptake: add 3H-CTP, incubate 0-2 h, wash, lyse, count radioactivity. (4) For phospholipid synthesis: treat with CTP (1-5 mM) plus 14C-choline or 14C-ethanolamine, incubate 4-24 h, extract lipids, separate by TLC, quantify radiolabeled phospholipids. (5) Cell viability: treat with CTP 0.1-20 mM for 24-72 h, MTT assay; CTP 1-5 mM is non-toxic.
|
| Animal Protocol |
(1) For cerebral ischemia: use male Sprague-Dawley rats (250-300 g) with MCAO (90 min) followed by reperfusion. (2) Administer CTP disodium IV (10-50 mg/kg) or IP (20-100 mg/kg) immediately after reperfusion. (3) Formulation: sterile saline or PBS pH7.0-7.4. (4) Evaluate neurological deficits (mNSS) at 24 h and 72 h. (5) At endpoint, collect brain, stain with TTC for infarct volume. (6) For lipid metabolism: use high-fat diet-fed mice, administer CTP (50-200 mg/kg IP or PO daily for 4-8 weeks), measure serum triglycerides, cholesterol, phospholipids by enzymatic assays.
|
| ADME/Pharmacokinetics |
Highly soluble in water (≥100 mg/mL). For cell culture, dissolve directly or prepare 100-500 mM stock in sterile water, adjust pH to 7.0-7.4, filter sterilize. For in vivo, dissolve in sterile saline or PBS at 10-50 mg/mL. Storage: powder at -20degC for 3 years; solution at -20degC for 6 months, -80degC for 1 year. Stable at neutral pH, hydrolyzes under acidic conditions.
|
| Toxicity/Toxicokinetics |
Endogenous metabolite, non-toxic at physiological levels. In vitro: CCK-8 on HEK293 or neuronal cells with CTP (1-20 mM, 48 h) shows IC50 >10 mM. In vivo: acute IV LD50 in rodents ~1000-2000 mg/kg. At high doses (>200 mg/kg IV), transient hypotension and bradycardia due to adenosine receptor activation. No significant hepatotoxicity, nephrotoxicity, or neurotoxicity at therapeutic doses. Clinical studies in humans (up to 1-2 g/day IV or PO) show safety. For research use only.
|
| Additional Infomation |
CTP disodium is a naturally occurring nucleoside triphosphate essential for RNA/DNA biosynthesis, phospholipid synthesis (Kennedy pathway), and glycoprotein synthesis. It is a substrate for CTP synthase (CTPS), the rate-limiting enzyme for CTP synthesis. CTP also acts as an agonist of P2X purinergic receptors, mediating calcium influx. Studied for neuroprotective effects in cerebral ischemia, traumatic brain injury, and Alzheimer's disease. Not FDA-approved as a drug; strictly for research use.
|
| Molecular Formula |
C9H14N3NA2O14P3
|
|---|---|
| Molecular Weight |
527.12
|
| Exact Mass |
526.948
|
| CAS # |
36051-68-0
|
| Related CAS # |
Cytidine-5'-triphosphate;65-47-4
|
| PubChem CID |
53384495
|
| Appearance |
White to off-white solid powder
|
| Density |
2.5g/cm3
|
| Boiling Point |
849.2ºC at 760 mmHg
|
| Flash Point |
467.4ºC
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
31
|
| Complexity |
838
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])OP(=O)(O)O)O)O.[Na+].[Na+]
|
| InChi Key |
NFQMDTRPCFJJND-WFIJOQBCSA-L
|
| InChi Code |
InChI=1S/C9H16N3O14P3.2Na/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18;;/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H2,10,11,15)(H2,16,17,18);;/q;2*+1/p-2/t4-,6-,7-,8-;;/m1../s1
|
| Chemical Name |
disodium;[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphono phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~125 mg/mL (~237.14 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (189.71 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8971 mL | 9.4855 mL | 18.9710 mL | |
| 5 mM | 0.3794 mL | 1.8971 mL | 3.7942 mL | |
| 10 mM | 0.1897 mL | 0.9486 mL | 1.8971 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
